

# Molecular, biochemical characterization and assessment of immunogenic potential of cofactor-independent phosphoglycerate mutase against *Leishmania donovani*: a step towards exploring novel vaccine candidate

RATI TANDON<sup>1</sup>, SHARAT CHANDRA<sup>2</sup>, RAJENDRA KUMAR BAHARIA<sup>1</sup>, PRAGYA MISRA<sup>1</sup>, SANCHITA DAS<sup>1</sup>, KEERTI RAWAT<sup>1</sup>, MOHAMMAD IMRAN SIDDIQI<sup>2</sup>, SHYAM SUNDAR<sup>3</sup> and ANURADHA DUBE<sup>1\*</sup>

<sup>1</sup> Division of Parasitology, Central Drug Research Institute, Lucknow, India

<sup>2</sup> Division of Structural and Molecular Biology, Central Drug Research Institute, Lucknow, India

<sup>3</sup> Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India

(Received 14 February 2017; revised 7 May 2017; accepted 8 June 2017; first published online 10 July 2017)

## SUMMARY

Despite immense efforts, vaccine against visceral leishmaniasis has yet not been developed. Earlier our proteomic study revealed a novel protein, cofactor-independent phosphoglycerate mutase (LdiPGAM), an important enzyme in glucose metabolism, in T helper cells type 1 (Th1) stimulatory region of soluble *Leishmania donovani* antigen. In this study, LdiPGAM was biochemically and molecularly characterized and evaluated for its immunogenicity and prophylactic efficacy against *L. donovani*. Immunogenicity of recombinant LdiPGAM (rLdiPGAM) was initially assessed in naïve hamsters immunized with it by analysing mRNA expression of inducible nitric oxide (NO) synthase (iNOS) and other Th1/T helper cells type 2 cytokines, which revealed an upregulation of Th1 cytokines along with iNOS. Immunogenicity of rLdiPGAM was further evaluated in lymphocytes of treated *Leishmania*-infected hamsters and peripheral blood mononuclear cells of *Leishmania* patients in clinical remission by various parameters, viz. lymphoproliferation assay and NO production (hamsters and patients) and levels of various cytokines (patients). rLdiPGAM induced remarkable Lymphoproliferative response and NO production in treated *Leishmania*-infected hamsters as well as in patients and increase in interferon gamma (IFN- $\gamma$ ), interleukin-12 (IL-12p40) responses in *Leishmania* patients in clinical remission. Vaccination with rLdiPGAM exerted considerable prophylactic efficacy (73%) supported by increase in mRNA expression of iNOS, IFN- $\gamma$  and IL-12p40 with decrease in transforming growth factor beta and interleukin-10. Above results indicate the importance of rLdiPGAM protein as a potential vaccine candidate against visceral leishmaniasis.

**Key words:** recombinant *Leishmania donovani* cofactor-independent phosphoglycerate mutase, molecular docking, immunogenicity, T-cell response, treated *Leishmania*-infected hamsters, *Leishmania* patients in clinical remission, prophylactic efficacy.

## INTRODUCTION

Among the different forms of the leishmaniasis, visceral leishmaniasis is the most dreaded one and usually fatal if not treated (Sundar and Chatterjee, 2006; Von Stebut, 2015). To date, chemotherapy is the main weapon in our arsenal to combat this disease, which endures major issues such as resistance, variable efficacy, toxicity, parenteral administration and longer courses of administration. In the absence of an appropriate chemotherapeutic option, development of an effective vaccine has become imperative for the management of visceral leishmaniasis (VL) (Sundar *et al.* 2001; Croft *et al.* 2006; Ait-Oudhia *et al.* 2011). The outcome of VL is the consequence of the immune response occurred in the host

wherein the systemic *Leishmania* infection is followed by an increase in *Leishmania*-specific antibodies. In addition, there is a suppression of T helper cells type 1 (Th1) cell-mediated immune response marked by downregulation of interferon gamma (IFN- $\gamma$ ) and interleukin-12 (IL-12) along with a significant up-regulation of T helper cells type 2 (Th2) cytokines as indicated by increase in the expression of interleukin-4 (IL-4) and interleukin-10 (IL-10) in lymphocytes (Kemp *et al.* 1994; Murray *et al.* 1997; Coler *et al.* 2002; Kumari *et al.* 2012). In contrast, there is a typical type 1 immune response with an augmentation in the levels of IFN- $\gamma$  and IL-2 as well as the infiltration of neutrophils, eosinophils and natural killer cells with an increase in IL-12 monocytes in the treated/cured cases (Karp *et al.* 1993; Kemp *et al.* 1999; Peruhype-Magalhaes *et al.* 2005). These observations imply that any intervention, which helps to divert the Th2 type of immune response to Th1, shall play a crucial role in the

\* Corresponding author: Division of Parasitology, Central Drug Research Institute, Post Box No. 173, Lucknow 226 031, India. E-mail: [anuradha\\_dube@hotmail.com](mailto:anuradha_dube@hotmail.com), [anuradha\\_dube@rediffmail.com](mailto:anuradha_dube@rediffmail.com)

management of VL. The search for parasite antigens, which could generate a desired Th1 type of cellular response should be primarily associated with the identification of novel proteins which can serve as a potential immunogen (Handman, 2001; Coler and Reed, 2005; Khalil *et al.* 2006).

*Leishmania donovani* cofactor-independent phosphoglycerate mutase (LdiPGAM) was earlier identified through proteomic study by our group in the Th1 stimulatory sub-fraction of soluble *L. donovani* promastigote antigen (SLD) of molecular weight ranging from 89.9 to 97.1 kDa (Gupta *et al.* 2007; Kumari *et al.* 2008b). Phosphoglycerate mutases are glycolytic enzymes, which are present in the cytoplasm of cells of different organisms, including plants, but over the last 20 years, their localization has been demonstrated in other organelles such as in cell wall of yeast, mitochondrion in *Arabidopsis* cells or in nucleoli of cancer cells, along with the cytoplasm (Wang *et al.* 1996; Giege *et al.* 2003; Gizak *et al.* 2015; Motshwene *et al.* 2003). PGAMs exist in two forms, which are kinetically and structurally distinguishable among the different organisms based on whether they require 2, 3-bisphosphoglycerate as cofactor or not for their functioning. The cofactor-dependent enzyme (dPGAM) is present in all vertebrates, while cofactor independent form (iPGAM) is present in almost all nematodes, bacteria and trypanosomes with the exception to some bacteria, such as *Escherichia coli* and certain archaea and protozoa that contain both the iPAGM and dPAGM forms (Chander *et al.* 1999; Chevalier *et al.* 2000; Jedrzejas *et al.* 2000; Guerra *et al.* 2004; Besteiro *et al.* 2005; Djikeng *et al.* 2007; Foster *et al.* 2010). iPGAM sequences show no apparent identity with those of dPGAMs. The studies performed on the reaction mechanism of iPGAMs demonstrated that the enzyme acts in a fundamentally different way than dPGAMs (Carreras *et al.* 1980). Phosphoglycerate mutase has been molecularly characterized as iPGAM only in cutaneous form of *Leishmania* i.e. *L. mexicana* (Guerra *et al.* 2004). As per our knowledge, iPGAM was identified by our group, for the first time, in immunogenic sub-fraction of soluble *L. donovani* lysate; therefore, we intend to evaluate its species-specific role. For the purpose, we first carried out molecular and biochemical characterization of iPGAM in *L. donovani*. Then, the ability of this recombinant protein (rLdiPGAM) to stimulate the immune responses was assessed in lymphocytes and peripheral blood mononuclear cells (PBMCs) of treated *Leishmania*-infected hamsters and *Leishmania* patients in clinical remission/endemic controls. The prophylactic potential of this recombinant protein was further assessed in hamsters against *L. donovani* infection.

Moreover, as this protein is unique to the parasite, there is a possibility that it can serve as a novel drug target. Therefore, development and validation of the

homology three-dimensional (3D) structure of LdiPGAM was done followed by virtual screening based on docking approach. Further, Maybridge database containing 53 000 chemical compounds targeting the substrate-binding site of LdiPGAM was explored to identify its inhibitors.

## MATERIALS AND METHODS

### Ethics statement

Experiments on the animals (hamsters) were executed following the approval of the protocol and the guidelines of Institutional Animal Ethics Committee (IAEC) of the CDRI (reference number 154/10/Para/IAEC/2011), which is adhered to National Guideline of CPCSEA (Committee for the Purpose of Control and Supervision on Experiments on Animals) under the Ministry of Environment and Forest, Government of India.

The protocol and study with patients was approved by the Ethics committee of the Kala-azar Medical Research Centre, Muzaffarpur (Protocol # ECKAMRC/Vaccine/VL/2007–01) and a prior written consent was taken from the patients (or the parents in case if the patient was minor) before the initiation of the study. A thorough clinical examination was done by a local physician of all the human subjects in the study for Leishmanial and other possible infections.

### Animals

Laboratory-bred male golden hamsters (*Mesocricetus auratus*, 45–50 g) from the Institute's animal house facility were used as hosts for the experiments. They were housed in a climatically controlled room and fed with standard rodent food pellet (Lipton India, Mumbai, India) and water *ad libitum*. The experimental animals were monitored daily till the termination of the study. In order to reduce the suffering level in experimental animals, hamsters were autopsied at the endpoint by deep anaesthesia with over dosages of sodium thiopentone (50 mg kg<sup>-1</sup>).

### Parasites and macrophage cell line

*Leishmania donovani* clinical strain (2001), which is SAG-sensitive isolate, was procured from a Kala-azar patient from Banaras Hindu University, Varanasi Uttar Pradesh, India, in the year 2000. The promastigotes were cultured in complete Roswell Park Memorial Institute-1640 (RPMI-1640) medium containing 10% heat-inactivated fetal bovine serum (Sigma, USA), 100 U mL<sup>-1</sup> penicillin (Sigma) and 100 mg mL<sup>-1</sup> streptomycin (Sigma) at 26 °C. The maintenance of parasite was also carried out in hamsters through serial passages (i.e., from amastigote to amastigote) (Dube *et al.* 2005).

Mouse macrophage cell line J774A.1 obtained from the institute's Tissue culture facility was cultured in RPMI-1640 through sub-culture in 25 cm<sup>2</sup> flasks at kept at 37 °C and 5% CO<sub>2</sub>.

#### *Soluble L. donovani promastigote antigen*

SLD was prepared following the protocol described by Gupta *et al.* (2007). The estimation of protein content of the supernatant was done by the Bradford method and the antigen was stored at -70 °C till further use.

#### *Cloning, expression and purification of rLdiPGAM*

The designing of gene-specific primers was carried out according to the gene sequence of *L. mexicana* iPGAM available in the database. PCR amplification using the *L. donovani* genomic DNA as template was performed with the oligonucleotides: 5'-GGATCCA TGTCAGCACTTCTCTTGAAG-3' as a forward primer and 5'-GAATTCCTTCTCGACGTAGATCAGGCTAG-3' as reverse primer containing *Bam*HI and *Eco*RI restriction sites (underlined) respectively. Using 2× PCR Master mix (Fermentas, USA) LdiPGAM gene was amplified, and the product was inserted in-frame with a 6× His tag into pET-28a vector (Novagen, USA) at *Bam*HI/*Eco*RI site, and it was confirmed by sequencing. *E. coli* BL21-Codon plus (DE3) strain competent cells were used to express *L. donovani* rLdiPGAM and following standard procedure the recombinant protein with N-terminal His-tag was purified employing Ni-NTA agarose column beads (Qiagen, Germany) in lysis buffer (50 mM Tris, 500 mM NaCl and 10 mM imidazole; pH 8.0). The eluted protein was resolved on 12% sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and stained with the Coomassie Brilliant Blue stain (Sigma). The protein was quantified by the Bradford method using bovine serum albumin (BSA) as standard. The protein was also subjected to Limulus amoebocyte lysate test (QCL-1000, Lonza, USA) to detect the presence of endotoxin content.

#### *Polyclonal antibodies production against rLdiPGAM and Western Blotting*

The antibodies against purified rLdiPGAM protein were developed in Balb/c mice. Mice were first immunized with 25 µg of recombinant protein in Freund's complete adjuvant. The mice were given three booster doses of 10 µg protein, each in incomplete Freund's adjuvant, at 2-weeks interval and the serum was collected by sacrificing the mice on 8th day after the last immunization. The titre of antibody was verified by enzyme-linked immunosorbent assay (ELISA). For western blotting, purified protein, *Leishmania* promastigote whole cell lysate,

and SLD were resolved on 12% SDS-PAGE and transferred onto nitrocellulose membrane electrophoretically employing Hoefer Semiphor semi-dry blot apparatus (Hoefer, USA). The membrane, after blocking in 5% skimmed milk overnight, was incubated with anti rLdiPGAM antibodies (1:1000 dilution) for 2 h at room temperature (RT). After washing the membrane three times with phosphate buffer saline (PBS) + 0.5% Tween 20 (PBS-T), it was incubated with goat anti-mouse immunoglobulin G (IgG) horseradish peroxidase-conjugated antibody at a dilution of 1: 10 000 for 1 h at RT and then the blot was developed using the Enhanced chemiluminescence kit (Invitrogen, USA).

#### *Size exclusion chromatography*

Approximately 500 µL (~200 µg) of purified recombinant protein was loaded onto a Sephadex-75 10/300 column (GL column), which was pre-equilibrated with buffer (50 mM Tris-HCl, pH 7.2, 300 mM NaCl) using a manual injector. Chromatography was performed on an AKTA purifier system (GE Healthcare, USA) at a flow rate of 0.3 mL min<sup>-1</sup> at 25 °C and the absorbance was monitored at 280 nm. The column was calibrated with standard molecular weight markers.

#### *Immunolocalization*

The promastigotes, washed with 1× PBS, were stained with Mito Tracker dye (500 nm in PBS, Invitrogen, USA) for 20 min. The cells were then washed with PBS, fixed in paraformaldehyde and allowed to adhere to poly-(L-lysine)-coated coverslips. Thereafter, the permeabilization of the parasites was done using 0.2% (v/v) Triton X-100 and they were washed again with PBS. The fixed cells were incubated for 30 min in PBS containing 3% BSA and washed again with PBS solution. Following this the parasites were incubated with mouse anti-LdiPGAM primary antibody at a dilution of 1: 10 000 for 1 h, washed with PBS and were incubated again for 1 h with FITC-conjugated goat anti-mouse IgG. The coverslips, after washing with PBS were treated with PBS containing Propidium Iodide (2 µg mL<sup>-1</sup>). Then, these were mounted on fresh slides using 10 µL of Fluorescent mounting media (Merck) and finally observed under confocal laser-scanning microscope (Olympus Fluoview FV1000, Japan). The negative control samples, which were devoid of primary antibodies were processed in parallel to negate background fluorescence.

#### *Leishmania cell synchronization and analysis of LdiPGAM expression in different stages of cell cycle*

*Leishmania donovani* cultures were synchronized by treating log phase cultures (2–3 × 10<sup>7</sup> cells mL<sup>-1</sup>)

with 5 mM hydroxyurea (HU) for 12 h. Afterward, parasites were harvested, washed twice with PBS and released into a drug-free RPMI-1640 medium, as described previously (Minocha *et al.* 2011). For flow cytometric analysis  $1-2 \times 10^7$  synchronized promastigotes were harvested at different time intervals after HU treatment, washed with PBS, fixed in 30% PBS + 70% methanol overnight at 4 °C, collected by centrifugation, washed with PBS, and stained in PBS containing propidium iodide ( $10 \mu\text{g mL}^{-1}$ ) as well as RNase ( $10 \mu\text{g mL}^{-1}$ ) at 37 °C for 30 min. Flow cytometric analysis was carried out using a BD FACS Calibur™ flow cytometer and the CellQuest Pro software (BD Biosciences, USA). G1, S and G2/M phases are indicated on the histograms by the gates M1, M2 and M3, respectively, which were derived from the data using the CellQuest Pro software. LdiPGAM expression in synchronized cells was analysed at different times by western blot analysis (10% PAGE) of whole cell extracts of  $2 \times 10^7$  using anti-LdiPGAM antibody (1:1000 dilution). Quantitative assessment was carried out with Image-J software (NIH IMAGE) and the expression level was normalized to Grp78.

#### Kinetic analysis of rLdiPGAM

**Enzyme assays.** The enzymatic activity of rLdiPGAM was measured by following either the increase of UV absorbance at 240 nm due to phosphoenolpyruvate (PEP) production (molar extinction coefficient  $1310 \text{ M}^{-1} \text{ cm}^{-1}$ ) or the decrease in UV absorbance at 340 nm due to nicotinamide adenine dinucleotide hydrate (NADH) oxidation (molar extinction coefficient  $6250 \text{ M}^{-1} \text{ cm}^{-1}$ ) (1) using a spectrophotometer (Spectra<sub>Max</sub>, USA).

**PEP production, forward reaction.** The reaction was followed upon the addition of 1.5 mM 3-phosphoglycerate (3PGA) into a 1 mL quartz cuvette containing 50 mM Tris-HCl (pH 7.6), 0.55 U of rabbit muscle enolase (ENO), 1 mM  $\text{MgCl}_2$ , 0.1 mM  $\text{CoCl}_2$  and 50 mM KCl. One activity unit (U) is defined as the conversion of  $1 \mu\text{mol}$  substrate  $\text{min}^{-1}$  under standard conditions. Auxiliary enzymes used were obtained from Sigma-Aldrich, USA.

**NADH oxidation, reverse reaction.** The conversion of 2-phosphoglycerate (2PGA) to 3PGA was coupled to NADH oxidation by glyceraldehyde-3-phosphate dehydrogenase (GAPDH) via 3-phosphoglycerate kinase (PGK). The assay was carried out at 25 °C in a 1 mL reaction mixture containing 0.1 M Tris-HCl pH 7.6, 5 mM  $\text{MgCl}_2$ , 1 mM dithiothreitol, 1 mM ATP, 0.56 mM NADH, 0.01 mM  $\text{CoCl}_2$ , 0.8 mM 2PGA and GAPDH and PGK both at  $6 \text{ U mL}^{-1}$ .

Kinetic constants were determined using freshly purified rLdiPGAM. As NaCl,  $\text{CoCl}_2$  and imidazole

are required for the stability of the recombinant protein (Guerra *et al.* 2004), the recombinant enzyme was pre-dialysed against 50 mM Tris-HCl (pH 7.6), 100 mM NaCl, 0.1 mM  $\text{CoCl}_2$  and 50 mM imidazole (so as to get its optimum activity) and protein concentration was determined. For  $K_m$  calculation of forward reaction 11 assays were performed spanning a range of different concentrations of 3PGA from 0.05 to 3.0 mM. For  $K_m$  calculation of the reverse reaction, eight assays were performed spanning different concentrations of 2PGA ranging from 0.05 to 0.4 mM. Optimum curve fitting of data to the Lineweaver-Burk equation was calculated.

The pH optima of LdiPGAM were determined using forward reaction in Tris-HCl buffer at various pH ranging between 3.0 and 9.0.

**Homology modelling and molecular docking studies of LdiPGAM.** The sequence of LdiPGAM consisting of 553 amino acid residues was retrieved from the Uniprot database (accession code: D7R810). This sequence was used as a query for NCBI Blastp to search a suitable template. The LdiPGAM homology modelling was done using the crystal structure of *Leishmania mexicana* cofactor-independent phosphoglycerate mutase (LmiPGAM) (PDB ID: 3IGZ) (Nowicki *et al.* 2009) as the template. ClustalW program (Chenna *et al.* 2003) was used to perform sequence alignment. For the homology modelling MODELLER9.10 (Sali and Blundell, 1993) software was used, that generated 20 models for LdiPGAM and rated according to GA341 and DOPE scoring functions available with it. 'Loopmodel' class present in MODELLER was used for the refinement of loop regions. The best quality predicted 3D structure was selected using PROCHECK, which was used for further study (Laskowski *et al.* 1993). All the analysis and visualization of the structure files were done using chimera (Pettersen *et al.* 2004).

To validate the active site of modelled protein and to check the reliability of our docking program, first 3PGA was docked into modelled LdiPGAM structure using the program DOCK6.5 (Pettersen *et al.* 2004). Also for the *in silico* screening of over 53 000 compounds of Maybridge screening database, this DOCK6.5 program was utilized. The Maybridge database was prepared by converting all the structures present in it into 3D mol2 format from the 2D sdf format using CONCORD module of SYBYL7.1 program [SYBYL Molecular Modeling System Version 7.1 (2005), Tripos Inc., St. Louis, MO]. For docking studies, protein preparation and docking procedures were performed according to the standard protocol implemented in DOCK6.5. On the receptor surface, receptor spheres were placed using the sphgen program within the DOCK package. By using grid program of DOCK package, receptor electrostatic and VDW grid points were calculated. Each Maybridge screening

compound was docked as a flexible body in different orientation and energy minimization was enabled. The ligand–receptor interaction energy predicted by DOCK6 is based on the grid method and it is calculated as the sum of electrostatic and van der Waals components. The conformation of each of the ligand with most favourable interaction energy was chosen for further study.

**Enzyme inhibition assay.** The top five scoring compounds from Maybridge library were selected for enzyme inhibition assay.

Forward reaction, in which PEP production is measured, was used for the enzyme inhibition assay. All the test compounds were dissolved in dimethyl sulfoxide (DMSO) at 0.5 M concentration. Dilution with triple distilled water was carried out to make their final concentrations of 10, 25, 50 and 100  $\mu\text{M}$  for each test compound. The final concentrations of DMSO used were 0.00002, 0.00005, 0.0001 and 0.0002% (in 10, 25, 50 and 100  $\mu\text{M}$  of the test compounds, respectively). The inhibition assay was carried out by preincubating 20  $\mu\text{g}$  of LdiPGAM with 10, 25, 50 and 100  $\mu\text{M}$  concentrations of each compound (inhibitors) for 1 h at 37 °C. The reaction started with the addition of the enzyme reaction buffer (50 mM Tris–HCl, pH 7.6) and other substances as described above into the LdiPGAM–inhibitor mixture to reach the final volume of 1 mL. The blank wells contain all components of the reaction mixture including DMSO, but not any test compound to check any detergent effect. Furthermore, in order to ascertain that the inhibitory effect of the compounds were specific for LdiPGAM and not for the auxiliary enzyme ENO, activity of the ENO enzyme was assessed in the presence of different concentrations of the inhibitors by measuring PEP production using 2PGA as the substrate. The assay was performed at 25 °C in a 1.0 mL reaction mixture containing 50 mM Tris–HCl (pH 7.5), 1 mM  $\text{MgCl}_2$ , 50 mM KCl and 1 mM 2PGA. All the assays were performed in three replicates, and their means were calculated.

*Immunogenicity of rLdiPGAM in lymphocytes/PBMCs of treated Leishmania infected hamsters and Leishmania patients in clinical remission*

**Treatment of *L. donovani*-infected hamsters and isolation of lymphocytes.** The hamsters (~20) were intracardially infected with  $10^7$  *L. donovani* amastigotes and assessed for parasitic burden by splenic biopsy 1 month later as mentioned earlier (Singh *et al.* 2008). Those animals which harbour 25–30 amastigotes/100 macrophage cell nuclei were then subjected to the antileishmanial therapy with Miltefosine (Zentaris, Germany) continually for 5 days at a dose schedule of 40 mg  $\text{kg}^{-1}$  body weight. On day 30 post treatment the animals were

reexamined for the clearance of parasites by performing splenic biopsy.

For lymphoproliferative assay and NO production the lymph node cell suspension obtained from mesenteric lymph nodes of normal (uninfected), *L. donovani* infected (untreated) as well as treated hamsters as per the procedure described by Garg *et al.* (2005). The cells were counted and a suspension of  $10^6$  cells  $\text{mL}^{-1}$  was made in complete RPMI 1640 medium.

**Human samples and isolation of PBMCs.** Human samples were taken as per study groups described below:

- (1) Seven *Leishmania* patients in clinical remission (four males and three females, age ranging from 5 to 40 years) from hyperendemic areas of Bihar. The *Leishmania* patients, treated with a complete course of amphotericin B were checked for the parasite clearance in splenic aspirates. Blood samples were collected from these patients 2 months to 1 year post treatment.
- (2) Seven endemic controls (four males and three females; age range 15–45 years) belonging to the family of infected and/or *Leishmania* patients in clinical remission (household contacts) that neither showed clinical symptoms nor received any treatment for Kala-azar.
- (3) Seven *Leishmania*-infected patients (three males and four females, age range 5–40 years) showing clinical symptoms of Kala-azar.
- (4) Seven normal healthy donors (three males and four females, age range 25–30 years) from non-endemic areas, without any history of leishmaniasis, served as negative control.

The study was approved by the ethics committee of the Kala-azar Medical Research Centre, Muzaffarpur, India (protocol number ECKAMRC/Vaccine/VL/2007-01).

Heparinized venous blood (10 mL each) was collected from all of the study subjects, and PBMCs were isolated from blood by Ficoll–Hypaque density gradient centrifugation (Histopaque 1077; Sigma-Aldrich) as described by Garg *et al.* (2005). After determining the cell viability by trypan blue staining method, the  $10^6$  cells  $\text{mL}^{-1}$  was resuspended in a complete RPMI 1640 medium and was used for following immunological assays:

*Assessment of lymphocyte proliferative responses.*

The assay for lymphoproliferative responses was done following the method of Garg *et al.* (2005) with slight modifications, wherein, a non-radioactive XTT [2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide] reagent (Roche Diagnostics, USA) was used instead of radioactive [ $^3\text{H}$ ] thymidine. Lymph node cell suspension from hamsters or PBMCs from human blood samples

( $1 \times 10^6$  cells  $\text{mL}^{-1}$ ) was cultured in 96-well flat-bottom tissue culture plates (Nunc). The cells were stimulated with 100  $\mu\text{L}$  of mitogens [phytohaemagglutinin (PHA; Sigma-Aldrich, USA) for human PBMCs and concanavalin A (Sigma-Aldrich, USA) for hamster's lymphocytes] as well as antigens (rLdiPGAM and SLD) in triplicate at a concentration of 10  $\mu\text{g mL}^{-1}$  for each of PHA, Con A, rLdiPGAM and SLD. The cultures were kept at 37 °C in a CO<sub>2</sub> incubator with 5% CO<sub>2</sub> for 3 and 5 days respectively for mitogens and antigens. After that, 50  $\mu\text{L}$  of XTT (Roche Diagnostics, USA) was added to each well and the cultures were incubated further for 4 h. Finally, the absorbance was measured at 480 nm with 650 nm as reference wavelength.

#### *Induction of NO production by in hamster lymphocytes/PBMCs from patients*

The lymph node cells from hamsters (or PBMCs from patients) were suspended in a culture medium, plated at  $10^5$  cells  $\text{well}^{-1}$ , and stimulated for 3 days in case of mitogen (LPS) and 5 days in case of antigens (rLdiPGAM, SLD) at 10  $\mu\text{g mL}^{-1}$ . The presence of NO was assessed using Griess reagent (Sigma-Aldrich, USA) in the culture supernatants of macrophage cell lines (J774 A.1) after the exposure with supernatant of stimulated lymphocytes. The supernatants (100  $\mu\text{L}$ ) collected from macrophage cultures 24 h after incubation was mixed with an equal volume of Griess reagent and left for 10 min at RT. The absorbance of the reaction was measured at 540 nm in an ELISA reader (Ding *et al.* 1988). The nitrite concentration in the macrophages' culture supernatant samples was extrapolated from the standard curve plotted with sodium nitrite.

*Assessment of cytokine levels-IFN- $\gamma$ /interleukin-12 (IL-12p40)/IL-10 in lymphocytes of cured/ endemic patients.* Culture of PBMCs ( $1 \times 10^6$  cells  $\text{mL}^{-1}$ ) from human patients was set up in 96-well culture plates, and rLdiPGAM was added at a concentration of 10  $\text{mg mL}^{-1}$  in triplicate wells. The level of IFN- $\gamma$ , interleukin-12 (IL-12p40) and IL-10 was estimated by ELISA kit (OptEIA set; BD Pharmingen, USA) after 5 days of incubation with antigens using supernatants. The results were expressed as pictogram (pg) of cytokine  $\text{mL}^{-1}$ , based on the standard curves of the respective cytokine provided in the kit. The lower detection limits for various cytokines were as follows: 4.7 pg  $\text{mL}^{-1}$  for IFN- $\gamma$ , 7.8 pg  $\text{mL}^{-1}$  for IL-12p40 and 7.0 pg  $\text{mL}^{-1}$  for IL-10.

*Determination of in vivo immunomodulation by LdiPGAM in naïve hamster.* Two groups of animals each containing five hamsters were immunized intradermally (i.d.) on the back with rLdiPGAM (50  $\mu\text{g}$ ) and PBS, respectively. After 15 days, a booster

dose of half of the amount of antigen and PBS each was given to the hamsters of both the experimental groups. Thirty days later, the animals were sacrificed, and their spleens were isolated to extract RNA to assess the level of cytokines by quantitative real-time polymerase chain reaction (qRT-PCR).

*Quantification of mRNA cytokines and inducible NOS in hamsters by qRT-PCR.* qRT-PCR was performed to assess the expression of mRNAs for various cytokines and inducible NO synthase (iNOS) in splenic cells. Splenic tissues were taken from each of the three randomly chosen animals. Total RNA was isolated using TRI reagent (Sigma-Aldrich, USA) and quantified by using Gene-quant (Bio-Rad, USA). One microgram of total RNA was used for the synthesis of cDNA using a first-strand cDNA synthesis kit (Fermentas, USA). For real-time PCR, primers were designed using Beacon Designer software (Bio-Rad, USA) on the basis of cytokines and iNOS mRNA sequences available on PubMed (Melby *et al.* 1998a) (Table 1). qRT-PCR was conducted as per the protocol described earlier (Samant *et al.* 2009) by using SYBR Green PCR master mix (Bio-Rad, USA). Results were expressed as the fold expression change of mRNA level between control and experimental groups.

*Vaccination with rLdiPGAM in hamsters.* For immunization, a total of 60 Syrian golden hamsters (40–45 g) were divided into four groups, each containing 15 animals, wherein groups 1 and 2 served as normal control as well as infected controls, respectively, while groups 3 and 4 as the Bacillus Calmette–Guérin (BCG) as well as vaccinated groups. The hamsters of group 4 were injected i.d. with 100  $\mu\text{g}$  of rLdiPGAM in 100  $\mu\text{L}$  PBS along with equal volume of BCG. Fourteen days later, a booster dose of 50  $\mu\text{g}$  of rLdiPGAM + BCG was given i.d. to group 4. Day 21 after vaccination, each animal of groups 2, 3 and 4 was challenged intracardially with  $1 \times 10^6$  amastigotes of the clinical strain of *L. donovani*. On days 45 and 60 post challenge (p.c.), three to five hamsters per group were necropsied for the assessment of parasitological and immunological (Lymphoproliferation, NO, cytokines by RT-PCR and antibody level by ELISA) progression of VL (Gupta *et al.* 2012). The assessment of parasitic burden was made by counting the number of amastigotes per 1000 cell nuclei in the impression smears of different organs, namely spleen, liver and bone marrow (femur bone) of experimental animals. The percentage estimation of inhibition of parasite multiplication was done in comparison with the unvaccinated control using the following formula:

$$\frac{(\text{No. of parasite from infected control} - \text{No. of parasite from vaccinated group})}{\text{No. of parasite count from infected control}} \times 100$$

Table 1. Sequences of forward and reverse primers of hamster cytokines used for quantitative real time RT-PCR

Sl. no.	Primer	Primer sequence
1	HGPRT Forward	5'-GATAGATCCACTCCCATAACTG-3'
	Reverse	5'-TACCTTCAACAATCAAGACATTC-3'
2	TNF $\alpha$ Forward	5'-TTCTCCTTCCTGCTTGTG-3'
	Reverse	5'-CTGAGTGTGAGTGTCTGG-3'
3	IFN $\gamma$ Forward	5'-GCTTAGATGTCTGTAATGG-3'
	Reverse	5'-GCTGCTGTTGAAGAAGTTAG-3'
4	IL-12p40 Forward	5'-TATGTTGTAGAGGTGGACTG-3'
	Reverse	5'-TTGTGGCAGGTGTATTGG-3'
5	TGF $\beta$ Forward	5'-ACGGAGAAGAAGTCTGTG-3'
	Reverse	5'-GGTTGTGTTGGTTGTAGAGG-3'
6	IL-4 Forward	5'-GCCATCCTGCTCTGCCTTC-3'
	Reverse	5'-TCCGTGGAGTTCTTCCTTGC-3'
7	IL-10 Forward	5'-TGCCAAACCTTATCAGAAATG-3'
	Reverse	5'-AGTTATCCTTCACCTGTTCC-3'
8	iNOS Forward	5'-CGACGGCACCATCAGAGG-3'
	Reverse	5'-AGGATCAGAGGCAGCACATC-3'

Simultaneously, for evaluation of cellular and antibody responses at these time points, peritoneal exudate cells, mesenteric lymph nodes and blood were also collected to obtain cells and sera.

In addition, level of antileishmanial IgG antibodies and its isotypes was measured in sera samples of different experimental groups of hamsters following the slightly modified protocol of Samant *et al.* (2009). Briefly, overnight coating of 96-well ELISA plates (Nunc, USA) with rLdiPGAM (0.2  $\mu\text{g}/100 \mu\text{L well}^{-1}$ ) at 4 °C and blocking with 1.5% BSA at RT for 1 h was carried out. Sera were used as a primary antibody and added at a diluted ratio of 1:100 for 2 h at RT. Secondary antibodies in the dilution of 1/1000 form of Biotin-conjugated mouse anti-Syrian hamster IgG, IgG1 and biotinylated anti-Syrian hamster IgG2 (BD Pharmingen, USA) were added for 1 h at RT respectively and were incubated further for 1 h with peroxidase conjugated streptavidin at 1/1000 (BD Pharmingen, USA). Finally, after putting in the substrate O-phenylenediamine dihydrochloride (Sigma-Aldrich, USA), reading of the plate was taken at 492 nm.

*Post-challenge survival.* Six animals from each group were observed for their physical conditions and were given proper care, until their survival period. Mean survival period was calculated from the recorded survival data of individual hamster.

#### Statistical analysis

Two sets of experiments were performed and the results were expressed as mean  $\pm$  S.D. The analysis of the results was done by Student's *t* test and one-way ANOVA test followed by Dunnett's or Tukey's *post hoc* test, whichever was appropriate in each case, using the GraphPad Prism software program (GraphPad). The value of  $P < 0.05$  was considered as significant.

## RESULTS

### *rLdiPGAM* was cloned, expressed, purified and antibody against the protein was raised

The amplification and cloning of LdiPGAM gene was successfully carried out in pTZ57R/T (T/A) cloning vector (Fig. 1A and B). The gene was transformed into competent *E. coli* DH5 $\alpha$  cells and the positive ones were sequenced from Chromous Biotech Pvt. Ltd. The sequenced gene was submitted to the National Centre for Biotechnology Information (Accession no. HM044147). A sequence analysis using the NCBI database ([www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)) revealed that LdiPGAM has close similarity with *L. infantum* and other species of *Leishmania* (Supplementary Table S1). The gene was further sub-cloned into pET28a vector and the recombinant plasmid was characterized with double enzymatic digestion (Fig. 1C) and checked for overexpression. 1659 bp amplicon of LdiPGAM gene encoded 553 amino acids with a predicted molecular mass of ~60 kDa. Comparisons of both non-induced and induced culture in SDS-PAGE revealed that the protein was expressed successfully and the induced protein bands corresponded to its predicted size (Fig. 1D). Purification of His-tagged rLdiPGAM by metal affinity chromatography yielded of pure protein (Fig. 1D). The LPS content of the purified recombinant proteins was estimated to be below 5 endotoxin units (EU)/mg of the recombinant protein as measured by *Limulus* amoebocyte lysate test. Further, titre of the antibody produced against the recombinant protein was in the ratio of 1: 25 600 as determined by ELISA. Western Blotting using the antiserum to rLdiPGAM, detected single band at ~60 kDa in the soluble promastigote lysate, thus exhibiting its specificity (Fig. 1E). By size exclusion chromatography of this purified rLdiPGAM, a single elution peak at ~67 kDa was observed on Sephadex G-75 column




Fig. 1. Cloning overexpression, purification and raising of antibody against rLdiPGAM (A) Specific PCR of LdiPGAM; lane 1: 1 kb ladder, lanes 2–3: amplified PCR product at 1659 bp. (B) Clone confirmation in pTZ57R/T; lane 1: 1 kb ladder, lane 2: *Bam*HI/*Eco*RI digested pTZ57R/T + LdiPGAM, lane 3: Undigested plasmid (C) Clone confirmation in pET28a, Lane 1: 1 kb ladder, lane 2: *Bam*HI/*Eco*RI *HI* digested pET28a + LdiPGAM, lane 3: Undigested plasmid (D) Expression and purification of rLdiPGAM in *E. coli* cells; Whole Cell Lysate (WCL) of transformed *E. coli* separated on 10% acrylamide gel and stained with Coomassie Brilliant Blue. Lane 1: WCL before IPTG induction, lane 2: WCL after IPTG (1.0 mM) induction at 37 °C; lanes 3–5 wash fractions and lanes 6–8 eluted protein and lane 9: Molecular weight marker. (E) Western Blot analysis using anti-rLdiPGAM Ab in uninduced WCL, induced WCL and *Leishmania* WCL and soluble *Leishmania* antigen (SLD). Lane 1: Molecular weight marker; lane 2: Uninduced *E. coli* WCL; lane 3: induced *E. coli* WCL; lane 4: purified rLdiPGAM; lane 5: *Leishmania* WCL; and lane 6: SLD. (F) Size exclusion chromatographic profile of rLdiPGAM carried using a Sephadex-75 10/300 column (GL column) pre-equilibrated with buffer (50 mM Tris–HCl, pH 7.2, 300 mM NaCl). Single elution peak of rLdiPGAM was observed in chromatographic profile.

chromatography (Fig. 1F), which revealed the monomeric nature of the protein thus confirming the presence of cofactor-independent form of the enzyme in *L. donovani* parasite.

*Immunolocalization*

To find out the subcellular location of the rLdiPGAM protein, the immunolocalization studies was carried out, which revealed the presence of the enzyme in whole cytoplasm of the cell (Fig. 2A)

*Differential expression of LdiPGAM in different phases of cell cycle*

LdiPGAM expression was measured in different phases of cell cycle by synchronizing the cells. It was evident from flow cytometry analysis that HU treatment of the parasites was arresting *Leishmania* cell cycle at the G1/S phase boundary. At 12 h post HU treatment, most of the cells were found to be arrested in the G1 phase. When HU was removed, the parasites proceeded through the cell cycle. The cells returned to the log phase after 11 h as observed






Fig. 2. Intracellular localization of LdiPGAM and assessment of its expression in different stages of *Leishmania* cell cycle. (A) Immunofluorescence analysis of the intracellular distribution of LdiPGAM in *L. donovani* promastigotes: (i) merged image of all fields; (ii) kinetoplast labelling with mitotracker dye; (iii) immunolocalization image of LdiPGAM; (iv) cell nucleus and kinetoplasmic nucleus labelled with DAPI; (v) differential interference contrast image; (vi) merged image of all fluorescence images. (B) Flow cytometry analysis of hydroxyurea (HU)-treated synchronized cells harvested at different time intervals. (C) (i) Western Blot analysis (10% PAGE) of whole-cell extracts ( $2 \times 10^7$  cell equivalents) at different phases of cell cycle using anti-LdiPGAM antibody (1:1000 dilution); (ii) Bar chart represents mean and s.d. expression of LdiPGAM relative to grp78 in three independent experiments.

at regular interval of time (Fig. 2B). The expression of LdiPGAM was assessed in different phases of cell cycle by Western Blot analysis. Maximum expression of the protein was observed in G1 and S phases, which was decreased by  $\sim 4$ -fold in late S and G2/M phases [Fig. 2C(i) and (ii)].

#### Kinetic analysis of rLdiPGAM

The recombinant protein thus obtained has been subjected to a preliminary kinetic analysis. Under

the conditions described above, the following values for the Michaelis constants were measured: for the forward reaction, the  $K_m = 0.302 \pm 0.017$  mM for 3PGA substrate; for the reverse reaction, the  $K_m = 0.143 \pm 0.012$  mM for 2PGA. These  $K_m$  values of the recombinant were observed to be within the same range as reported for iPGAM from other organisms (Britton *et al.* 1971; Fothergill-Gilmore and Watson, 1989; Guerra *et al.* 2004; Erfe *et al.* 2012). Specific activity of the enzyme for forward and reverse reaction was

calculated as  $5.26$  and  $0.675 \mu\text{m min}^{-1} \text{mg}^{-1}$  of protein respectively. Optimum pH for the enzyme activity was found to be in the range of 7.5–8.

#### Homology modelling of LdiPGAM and molecular docking followed by enzyme inhibition assay

LdiPGAM has 92% of sequence identity with crystal structure of LmiPGAM, which was selected as its template for homology modelling (Fig. S1A), and the superimposition of the modelled complex with template shows a RMSD of  $0.149 \text{ \AA}$  (Fig. S1B). All models generated in MODELLER9.10 were analysed by SAVES server. Ramachandran plot generated by PROCHECK for the final selected model showed 93.2% residues in the most favoured region and 6.1, 0.6 and 0.0% residues lie in additional allowed region, generously allowed and disallowed region, respectively (Fig. S1C). The structure of protein made of 553 amino acid residues and consist of two domains namely phosphatase and transferase, which are present in close proximity with active site. The phosphatase domain starts from 84 residues located at N-terminal and the transferase domain (Ala92 to Asn326) is connected with phosphatase domain through first inter domain loop (Gly85 to Gly91). However, the transferase domain is connects back with phosphatase domain with second inter domain loop, which runs from Phe327 to Arg336. The active site interacts with the substrate as well as product and also the metal ion and it comprises 16 residues. The data from previous x-ray and crystallization studies suggest that iPGAM exists in equilibrium between two extreme conformations in which the two-domain monomer may be closed with an inaccessible active site, or open with an accessible active site. In the closed form the enzyme (as in Fig. S1B) catalyses 2/3PGA isomerization resulting in product release, and product release causes opening of the enzyme and return to the open conformation (Blackburn *et al.* 2014).

LdiPGAM is an important enzyme of glycolysis pathway, so inhibition of LdiPGAM has become an attractive target for the design of anti-leishmanial inhibitors. An additional advantage in choosing this as target is that LdiPGAM and human PGAM are not homologous and thus share no common features. On this basis, LdiPGAM was selected as the target receptor for docking of Maybridge screening database. The modelled structure of LdiPGAM in complex with metal ions was used for docking. Zinc parameters were used for docking. Modelled protein and template protein have 92% of sequence identity; consequently, they share identical active site and metal-binding site. The substrate 3PGA was extracted from the x-ray crystal structure of template protein, and then docked in the active site of LdiPGAM. The conformation of the docked substrate in modelled protein complex was found

similar to that of template protein and the substrate occupied the same active site as in template.

In the above-mentioned active site, approximately 53 000 small compounds of Maybridge screening database were docked in different orientations and ranked by energy score. The top five scoring compounds were selected for experimental testing and these compounds were found to display binding mode similar to that of the substrate within the active site of LdiPGAM, which was analysed visually. Our experimental results also show that two out of five selected compounds are inhibiting enzymatic activity significantly. Enzyme assays with forward reaction was performed to confirm the inhibitory role of these compounds on rLdiPGAM. TL00638 (1-methyl-1H-imidazole-4,5-dicarboxylic acid) exhibited maximum inhibitory activity followed by SPB00184 (2-hydroxyiminoindane-1,3-dione) as shown in Fig. S2A.  $IC_{50}$  for TL00638 and SPB00184 were observed to be  $37.3 \pm 0.9$  and  $60.9 \pm 3.5 \mu\text{M}$  (mean  $\pm$  S.D.), respectively. Moreover, these compounds did not affect the activity of the auxiliary enzyme ENO (data not shown), which indicates that the compounds are specific inhibitors of LdiPGAM. In order to reveal the mechanism of inhibition by these two compounds, kinetic analysis was performed, which showed the competitive inhibition of enzyme activity by these compounds (Fig. S2B). To understand the mechanism for the inhibition of LdiPGAM by two selected compounds, we analysed the docking modes of substrate as well as selected compounds in the active site of LdiPGAM. Both substrates and inhibitors fit well in the active site pocket with several hydrogen bond interactions with the active site residues. The binding conformation of these compounds is shown in Fig. S3. The substrate 3PGA of LdiPGAM, anchored to the cavity by the hydrogen-bonding interactions with Ser75, His136, Arg167, Arg202, Arg209, Arg282, Arg285 and His360. The nitrogen atom of imidazole group of compound TL00638 forms a hydrogen bond with side-chain N–H of Arg166 and Arg285. The oxygen atoms of the dicarboxylic acid group of this compound forms hydrogen bonds with Ser75, His136, Asp167, Arg202 and Arg282. A similar binding mode is also observed for the binding of compound SPB00184. Here cyclopentane moiety is basically involved in hydrogen bond interaction. The nitrogen of oxime group forms two hydrogen bonds with side-chain nitrogen of Arg209. The carbonyl oxygens attached with cyclopentane ring forms hydrogen bond with Ser75, Arg166, Arg282 and Arg285.

#### rLdiPGAM induced lymphoproliferation and NO production in treated *Leishmania*-infected hamsters

Assessment of cellular responses of lymphocytes from treated *Leishmania*-infected hamsters with

Con A as well as rLdiPGAM was done by XTT (Roche Diagnostics, USA) and was compared with that of SLD-stimulated group serving as control. The lymphocytes from normal as well as treated *Leishmania*-infected hamsters have revealed significantly higher proliferative responses when stimulated with Con A ( $P < 0.001$ ) as well as rLdiPGAM ( $P < 0.05$ ) in comparison with the SLD-stimulated ones (Fig. 3A); whereas in infected hamsters only Con A ( $P < 0.05$ ) induced significant proliferation than SLD.

The presence of NO was assessed in the culture supernatants of mouse J774A.1 macrophages after their exposure to supernatants of stimulated lymphocytes. There was 1.6-fold higher NO production in rLdiPGAM-stimulated cells as compared with SLD stimulated one ( $P < 0.05$ ) (Fig. 3B).

*rLdiPGAM induces PBMCs from Leishmania patients in clinical remission/endemic individuals to proliferate and to generate a predominant Th1 cytokine responses*

PBMCs from the patients in clinical remission, endemic and non-endemic controls and *L. donovani*-infected donors were used to further analyse their cellular and cytokine responses. Proliferation and cytokine responses of PBMCs from patients with active VL/cured/endemic against rLdiPGAM and SLD were compared, while PHA stimulation served as positive control. Since PHA is a mitogen, so all the groups stimulated with PHA showed significantly higher OD than SLD and rLdiPGAM ( $P < 0.001$  compared with SLD and  $P < 0.01$  with rLdiPGAM). Cells from the patients in clinical remission show better proliferative responses against rLdiPGAM with mean OD value of 1.087462, which is higher than SLD (0.708671) ( $P < 0.01$ ) (Fig. 4A). Similarly, rLdiPGAM induces significant NO production in PBMCs of patients in clinical remission and endemic controls ( $P < 0.05$ ) (Fig. 4B). The results indicate towards the recognition of rLdiPGAM as a potent T-cell antigen by majority of patients in clinical remission/endemic individuals.

For the assessment of the Th1/Th2 stimulatory potential of the rLdiPGAM, the level of cytokines viz. IFN- $\gamma$ , IL-12p40 and IL-10 were further estimated in the supernatant of stimulated PBMCs from infected and patients in clinical remission as well as in endemic and non-endemic individuals (Fig. 4C). IFN- $\gamma$  and IL-12p40 levels were found to be higher in the supernatants of patients in clinical remission with a range of 348–751 and 746–2336 pg mL<sup>-1</sup>, respectively, followed by endemic controls (256–432 and 164–1417 pg mL<sup>-1</sup>, respectively), whereas very low level of IL-10 cytokine against rLdiPGAM was detected in the supernatants of patients in clinical remission (90–211 pg mL<sup>-1</sup>) followed by endemic controls (ranging from 53 to




Fig. 3. Lymphoproliferative and NO response of rLdiPGAM in cured hamsters. (A) Lymphoproliferative response of mononuclear cells of lymph nodes from normal, and *L. donovani* infected and treated hamsters against recombinant protein/SLD. (B) NO production by peritoneal macrophages, in response to the recombinant protein/SLD stimulation. Results are expressed as means and s.d. for three to four hamsters per group done in triplicate and are representative of two independent experiments with similar results. The analysis of the results was done by the one-way ANOVA test followed by Tukey's post test. Significance values indicate the difference between the SLD and the recombinant proteins stimulation  $P < 0.05$  (\*),  $P < 0.01$  (\*\*) and  $P < 0.001$  (\*\*\*).

231 pg mL<sup>-1</sup>). Thus, there was a shift exclusively towards Th1 type of immune response stimulated by rLdiPGAM as evident by the production of high amounts of IFN- $\gamma$  and IL-12p40. There was suppression in the levels of IL-10, a Th1 deactivating cytokine, in patients with clinical remission as well as in endemic controls and a relatively low level of the same (as compared with SLD) in active cases. These findings indicate a precise and specific upregulation of Th1 stimulatory responses in patients in clinical remission with parallel downregulation of Th2 stimulatory responses.

*Immunization with rLdiPGAM favours the development of Th1-type cellular responses in naive hamsters*

To assess the immunogenicity of rLdiPGAM in modulating immune response of Th1/Th2 type, we further studied the status of iNOS transcript and Th1 (TNF- $\alpha$ , IFN- $\gamma$  and IL-12p40) and Th2 [transforming growth factor beta (TGF- $\beta$ ), IL-4 and IL-10] in naive hamsters on day 30 post immunization. The level of iNOS transcript was observed to be upregulated by ~3 folds in immunized




Fig. 4. Lymphoproliferative, NO and cytokine responses of rLdiPGAM in cured patients/endemic contacts. Lymphoproliferative (A) and NO (B) response of PBMCs from individuals of Cured VL patients and Endemic controls ( $n = 7$  for each group) against the recombinant proteins/SLD stimulation. The results were analysed by the one-way ANOVA test followed by Tukey's post test. Significance values indicate the difference between the SLD and the recombinant proteins' stimulation  $P < 0.05$  (\*),  $P < 0.01$  (\*\*) and  $P < 0.001$  (\*\*\*). (C) IL-12P40, IFN- $\gamma$  and IL-10 level of PBMCs from individuals of cured VL patients and endemic controls against the recombinant proteins/SLD. All measurements were done in triplicate in two independent experiments and the results were comparable.

hamsters as compared with unimmunised controls. mRNA expression of Th1 cytokines, IFN- $\gamma$  and IL-12p40, in rLdiPGAM immunized hamsters was observed to be significantly upregulated ( $P < 0.01$  and  $0.05$ , respectively) when compared with naive unimmunized controls. On the other hand, expression of Th2 cytokines, TGF- $\beta$  and IL-10, was found to be downregulated on day 30 p.i. ( $P < 0.001$  and  $0.05$ , respectively) in the immunized animals (Fig. 5).

*Vaccination with riPGAM generates considerably good prophylactic efficacy in hamsters against L. donovani challenges*

Prophylactic efficacy of rLdiPGAM was further evaluated along with BCG as an adjuvant, in

hamsters against *L. donovani* challenge. The vaccinated hamsters survived for a long duration post challenge and 67% ( $P < 0.001$ ) of animals remained alive and healthy till 6 months p.c. when the experiment was terminated. On the other hand, hamsters vaccinated with BCG and unvaccinated infected control could survive only up to 2–3 months (Fig. 6). There was a gradual weight loss in the animals of the infected and BCG control groups whereas in the vaccinated animals a weight gain with time ( $P < 0.05$  on day 45 p.c. and  $P < 0.01$  on day 60 p.c.) was observed as noticed in normal hamsters. A remarkable reduction of hepatosplenomegaly was also observed in the vaccinated group, which is usually associated with the *Leishmania* infection (Fig. 7A–C). With an exception to the




Fig. 5. Analysis of Splenic iNOS and cytokine mRNA expression profile by quantitative RT-PCR in normal and immunized hamsters on day 30 p.i. Results are presented as means and S.D. for five hamsters per group done in triplicate and are representative of two independent experiments with similar results. The analysis of the results was done by Student's *t* test. Significance values indicate the difference between the immunized group and normal group.  $P < 0.05$  (\*),  $P < 0.01$  (\*\*) and  $P < 0.001$  (\*\*\*).

rLdiPGAM vaccinated group, an increase in parasite number from  $3 \times 10^3$  to  $4 \times 10^3$  was noticed in Giemsa-stained splenic dab smears of all the experimental hamsters from days 45 to 60 p.c. (Fig. 7D). In the vaccinated group, parasite loads decreased substantially from  $2 \times 10^3$  on day 45 to  $0.5 \times 10^3$  by day 120 p.c. Similarly, a decrease in parasite loads was seen in liver and bone marrow, after day 45 p.c. in the same vaccinated group (Fig. 7E and F).

#### *rLdiPGAM* vaccination stimulates mitogenic, and *Leishmania*-specific cellular responses and alters *Leishmania*-specific IgG and its isotypes

rLdiPGAM vaccination in hamsters induces Con A-specific lymphoproliferative response similar to that observed in normal ones throughout the p.c. period (days 45 and 60), whereas it was lower in other control groups. A significant antigen-specific lymphoproliferative response ( $P < 0.001$ ) was observed in the cells of rLdiPGAM vaccinated hamsters when compared with hamsters vaccinated with BCG alone and infected control group wherein a lesser proliferative response was observed (Fig. 8A and B). The supernatant of rLdiPGAM-stimulated lymphocytes from vaccinated hamsters produced remarkable levels of NO ( $\sim 2.4$ -fold), which also supports the view regarding the upregulation of iNOS by Th1 cell-associated cytokines. Mouse J774A.1 macrophages line, when incubated with stimulated supernatants of lymphocytes from rLdiPGAM + BCG vaccinated hamsters, produced more significant ( $P < 0.001$ ) amounts of NO ( $14.36 \pm 2.18 \mu\text{M}$ ) than the other control groups ( $6.7$ – $6.9 \mu\text{M}$  values) on day 45 p.c., which further increased by day 60 p.c. (Fig. 8C and D).

The leishmanial antigen-specific IgG and its isotypes (IgG1 and IgG2) in sera of all the experimental




Fig. 6. Survival curve analysis of different experimental groups. Survival data of animals (six hamsters in each group), representative of two independent experiments with similar results was observed up to day 180 p.c.

groups were assessed by ELISA. There was a progressive increase with time in the levels of anti-*Leishmanial* IgG and IgG1 in all the groups, except the rLdiPGAM + BCG vaccinated group, wherein the level significantly remained at lower levels than that of infected and BCG controls. In contrast, there was a significant elevation ( $P < 0.001$ ) in the IgG2 level in rLdiPGAM + BCG vaccinated animals in comparison with the other experimental and control groups (Fig. 8E and F).

#### *rLdiPGAM* + BCG vaccination generates protective immune response of Th1 type in vaccinated hamsters

On days 45 and 60 p.c., the mRNA expressions of Th1 and Th2 cytokines i.e. TNF- $\alpha$ , IFN- $\gamma$ , IL-12p40, TGF- $\beta$ , IL-4 and IL-10 and iNOS were evaluated in rLdiPGAM + BCG vaccinated group and compared with *L. donovani* infected hamsters. There was a significant increase in the level of IL-12p40 at both the time points ( $P < 0.01$  at day 45 and  $P < 0.05$  at day 60 p.c.) as compared with the infected controls. The expression of iNOS and IFN- $\gamma$  mRNA transcript levels also increased significantly on days 45 and 60 p.c. ( $P < 0.001$ ). However, there was no significant elevation in TNF- $\alpha$  expression at both the time points ( $P > 0.05$ ); whereas, on the other hand, extreme downregulation in the expression levels of TGF- $\beta$  and IL-10 expressions was noticed in the vaccinated group on days 45 ( $P < 0.001$ ) and 60 p.c. ( $P < 0.001$  for TGF- $\beta$  and  $P < 0.05$  for IL-10) in comparison with the infected ones. However, the expression of IL-4 was not significant at all the time points (Fig. 9).

#### DISCUSSION

Regardless of a big repository of various vaccine candidates under different stages of development, no licensed vaccine is yet available against VL. A number of defined subunit vaccine candidates of several *Leishmania* species, are still at various




Fig. 7. Body weight, spleen weight and liver weight as well as parasite burden in rLdiPGAM + BCG vaccinated hamsters. Body weight (A), spleen weight (B) and liver weight (C) in g as well as parasite burden (no. of amastigotes per 10001 cell nuclei) in the spleen (D), liver (E) and bone marrow (F) of hamsters on days 0, 45, 90, 120 and 180 p.c. Results are means and S.D. for three to four hamsters per group done in triplicate and are representative of two independent experiments with similar results. The analysis of the results was done by the one-way ANOVA test followed by Tukey's post test. Significance values indicate the difference between infected group and other experimental groups  $P < 0.05$  (\*),  $P < 0.01$  (\*\*) and  $P < 0.001$  (\*\*\*)

experimental stages (Abdian *et al.* 2011; Bolhassani *et al.* 2011; Stober *et al.* 2012). LEISH-F1 + MPL-S.E. is the only second-generation vaccine, which was assessed for its safety and immunogenicity (Chakravarty *et al.* 2001) in India and is currently in clinical development for human VL (<http://clinical-trials.gov>). As a step towards identifying novel and effective vaccine candidates against VL, cofactor-independent phosphoglycerate mutase (iPGAM) was identified as one of the probable Th1 stimulatory protein in the soluble sub-fraction of *L. donovani* (SLD) antigens ranging from 89.9 to 97.1 kDa (Gupta *et al.* 2007; Kumari *et al.* 2008b), in one of our previous studies.

The gene analysis of LdiPGAM demonstrated its homology to *L. infantum* and other *Leishmania* spp. to the tune of 90–94% (Supplementary Table S1).

Moreover, when the relative expression of LdiPGAM was determined in different phases of cell cycle, there was maximum expression of protein in G1 and S phases and down expression in late S and G2/M phases, which supported the view that induction of glycolytic enzyme activities and increase of glycolytic rates during the G1 phase of the cell cycle are essential for cell process of RNA and DNA synthesis in the S phase (Brand *et al.* 1988). Bio-informatic approach led to the identification of two novel inhibitors of this protein molecule which, if explored, may further serve as drug candidates.

Since, LdiPGAM was recognized in immunogenic sub-fraction of SLD (Kumari *et al.* 2008a), we, further evaluated its immunogenicity, which showed that the recombinant protein stimulated better cellular immune response in treated




Fig. 8. Lymphoproliferative, NO and antibody responses in rLdiPGAM vaccinated hamsters. (A, B) LTT response in Con A and rLdiPGAM stimulated lymphocytes of rLdiPGAM + BCG-vaccinated hamsters in comparison with the unimmunized infected hamsters on days 45 and 60 p.c. (C, D) NO production following LPS and rLdiPGAM stimulation in lymphocytes of rLdiPGAM + BCG-vaccinated hamsters in comparison to the unimmunized infected hamsters on days 45 and 60 p.c. (E, F) Leishmanial antigen-specific IgG and its isotypes IgG1 and IgG2 in rLdiPGAM + BCG vaccinated hamsters in comparison with the unimmunized infected hamsters on days 45 and 60 p.c. Data are presented as mean absorbance  $\pm$  s.d. for three to four hamsters per group in triplicate wells and are representative of two independent experiments with similar results. The analysis of the results was done by the one-way ANOVA test followed by Tukey's post test. Significance values indicate the difference between the vaccinated group and infected group  $P < 0.05$  (\*),  $P < 0.01$  (\*\*) and  $P < 0.001$  (\*\*\*)

*Leishmania*-infected hamsters as compared to SLD. Though, many studies have been conducted with SLD (Garg *et al.* 2006; Kumari *et al.* 2008a, b), the response generated thereof was found to be partially protective and moreover cannot be specified due to the presence of multiple proteins whereas the immunogenic responses generated against rLdiPGAM are specific and better as compared to SLD. Moreover, major problems with the fractionated vaccines for human applications are their production to good clinical manufacturing standards, as well as gene variation and polymorphisms in field isolates. On the other hand, refined vaccines, such as recombinant proteins, have more feasible application for mass vaccination (Kumar and Engwerda, 2014).

We further evaluated the cellular immune response of the recombinant protein in hamsters in

order to correlate the experimental observations with the human samples. Hamster serves as a good model of the systemic *L. donovani* infection as disease pathogenesis mimics to human Kala-azar patients (Melby *et al.* 2001). Herein, the immunogenicity of rLdiPGAM observed in hamsters, corroborated well in VL patients that were treated with amphotericin B as well as in endemic controls.

Further, since, it is well known that in case of leishmanial infection, macrophages, activated by IFN- $\gamma$  released from parasite-specific T cells, are able to destroy intracellular parasites through the production of several mediators particularly NO (Liew *et al.* 1991; Assreuy *et al.* 1994). Herein, rLdiPGAM induced significantly higher proliferative responses and NO production in lymphocytes of treated *Leishmania*-infected hamsters as compared to normal as well as infected ones.




Fig. 9. Splenic iNOS and cytokine mRNA expression profile analysis of normal and vaccinated hamsters on days 45 and 60 p.c. by the qRT-PCR. Results are means and s.d. for three to four hamsters per group done in triplicate and are representative of two independent experiments with similar results. The results were analysed by the one-way ANOVA test followed by Tukey’s post-test. Significance values indicate the difference between the vaccinated group and infected group  $P < 0.05$  (\*),  $P < 0.01$  (\*\*) and  $P < 0.001$  (\*\*\*)

Since, it is a well-known fact that the recovery of individuals from leishmanial infection depends on the shifting of the immune response towards Th1 type (Belosevic *et al.* 1989; Holaday *et al.* 1991), with the release of IL-12p40 and IFN- $\gamma$  (MacMicking *et al.* 1997; Kumari *et al.* 2008a) the immunogenicity in terms of Th1 and Th2 cytokines being produced in response to rLdiPGAM was further assessed. The high level of IFN- $\gamma$  and

IL-12p40, and suppressed level of IL-10 in endemic control as well as in *Leishmania* patients in clinical remission indicate towards the immunogenic potential of this protein.

As a first step towards translating our data *in vivo*, the immunogenic potential of the rLdiPGAM was evaluated (post immunization) in naïve hamsters as compared with the unimmunized ones. The shifting of cellular immune response towards Th1 arm as



indicated by the increased level of mRNA transcripts of iNOS and Th1 cytokines particularly IFN- $\gamma$  further ascertained towards the potential of the protein in study as a novel vaccine candidate against VL.

The ability of rLdiPGAM to stimulate a strong Th1-type immune response encouraged us to assess its prophylactic efficacy along with BCG as an adjuvant, in hamsters against *L. donovani* challenge. BCG had been used in adjunct to several immunological agents (Khalil *et al.* 2000; Misra *et al.* 2001), due to its ability to activate macrophages to generate NO for its microbicidal functions as reported by Armijos *et al.* (2004) and Nozaki *et al.* (1997). Vaccination with rLdiPGAM + BCG have exerted considerably good prophylactic efficacy (73%) (Samant *et al.* 2009; Gupta *et al.* 2012; Kushawaha *et al.* 2012) against *L. donovani* challenge in hamsters and approximately 67% of vaccinated animals could survived up to 6 months p.c. supported by a strong cell mediated immunity (CMI) response.

One measure among the several parameters of CMI, is mitogen and antigen-specific proliferation related to T-cell stimulation *in vitro*, which almost relates the control of parasite multiplication and healing in animals and humans (Melby *et al.* 1998a, b; Armijos *et al.* 2004; Baharia *et al.* 2014). Since, during active VL there is an impairment of T-cell proliferation (Kumar and Nylén, 2012) the rLdiPGAM vaccination stimulated ~2-folds T-cell proliferation in hamsters after *L. donovani* challenge in comparison with the other experimental and control groups. However, since lymphoproliferation could not be regarded as the primary effector functions against the parasite, NO production by activated macrophages upon stimulation of *Leishmania*-specific T-cells has been considered to be the prominent and primary phenomenon of eliminating the intracellular parasite (Scott *et al.* 1987). In the present study also, a gradual increase in NO production (~2–3-folds) in the supernatant of macrophages co-stimulated with supernatant of rLdiPGAM-stimulated lymphocytes from vaccinated hamsters was noticed which also sustains the observation related to the upregulation of iNOS by Th1 cell-linked cytokines (Armijos *et al.* 2004). In addition, the vaccinated hamsters demonstrated higher IL-12p40 and IFN- $\gamma$  cytokine levels along with remarkable downregulation of IL-10 and TGF- $\beta$  as estimated by quantitative real-time PCR. The observation was well supported by the augmentation in the level of *Leishmania*-specific IgG2, which is also a sign of enhanced CMI (Kushawaha *et al.* 2011).

In a nutshell, the rLdiPGAM, an enzyme of glycolytic pathway, is competent enough of inducing a strong cellular immune response *in vitro* as well as eliciting a moderate protective response against

experimental VL *in vivo* in hamster model. Since, there is no effective vaccine as yet, the potential of this novel vaccine candidate could be validated and explored further for the optimization either alone or in combination with other potential vaccine candidates or adjuvants. Moreover, as a scope for more in-depth exploration, future study could be directed towards the identification and synthesis of immunodominant epitopes of this protein, which would generate more specific and robust T-cell response.

#### SUPPLEMENTARY MATERIAL

The supplementary material for this article can be found at <https://doi.org/10.1017/S0031182017001160>.

#### ACKNOWLEDGEMENTS

The authors are grateful to the Director of CDRI/CSIR, Lucknow for providing the facilities to make this study possible. The authors are thankful to Mr. A. L. Vishwakarma, SAIF, CDRI, Lucknow for providing Flow Cytometry study. This manuscript bears CSIR-CDRI communication no. 9513.

#### FINANCIAL SUPPORT

This work was supported by a grant from CSIR Network Project (HOPE-BSC0114) and Department of Biotechnology, New Delhi (BT/PR11782/MED/29/113/2009; Dated: 15.09.2009). Computational work was supported by grant from CSIR Network project GENESIS (BSC0121). The Council for Scientific and Industrial Research, New Delhi provided Junior (JRF-2 years) as well as Senior Research Fellowship (SRF-3 years) to R.T.

#### CONFLICT OF INTEREST

None.

#### REFERENCES

- Abdian, N., Gholami, E., Zahedifard, F., Safaee, N. and Rafati, S. (2011). Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against *Leishmania major* infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis. *Experimental Parasitology* **127**, 627–636.
- Ait-Oudhia, K., Gazanion, E., Vergnes, B., Oury, B. and Sereno, D. (2011). *Leishmania* antimony resistance: what we know what we can learn from the field. *Parasitology Research* **109**, 1225–1232.
- Armijos, R. X., Weigel, M. M., Calvopina, M., Hidalgo, A., Cevallos, W. and Correa, J. (2004). Safety, immunogenicity, and efficacy of an autoclaved *Leishmania amazonensis* vaccine plus BCG adjuvant against New World cutaneous leishmaniasis. *Vaccine* **22**, 1320–1326.
- Assreuy, J., Cunha, F. Q., Epperlein, M., Noronha-Dutra, A., O'Donnell, C. A., Liew, F. Y. and Moncada, S. (1994). Production of nitric oxide and superoxide by activated macrophages and killing of *Leishmania major*. *European Journal of Immunology* **24**, 672–676.
- Baharia, R. K., Tandon, R., Sahasrabudhe, A. A., Sundar, S. and Dube, A. (2014). Nucleosomal histone proteins of *L. donovani*: a combination of recombinant H2A, H2B, H3 and H4 proteins were highly immunogenic and offered optimum prophylactic efficacy against *Leishmania* challenge in hamsters. *PLoS ONE* **9**, e97911.
- Belosevic, M., Finbloom, D. S., Van Der Meide, P. H., Slayter, M. V. and Nacy, C. A. (1989). Administration of monoclonal anti-IFN-gamma antibodies *in vivo* abrogates natural resistance of C3H/HeN mice to infection with *Leishmania major*. *Journal of Immunology* **143**, 266–274.

- Besteiro, S., Barrett, M.P., Riviere, L. and Bringaud, F. (2005). Energy generation in insect stages of *Trypanosoma brucei*: metabolism in flux. *Trends in Parasitology* **21**, 185–191.
- Blackburn, E.A., Fuad, F.A., Morgan, H.P., Nowicki, M.W., Wear, M.A., Michels, P.A., Fothergill-Gilmore, L.A. and Walkinshaw, M.D. (2014). Trypanosomatid phosphoglycerate mutases have multiple conformational and oligomeric states. *Biochemical and Biophysical Research Communications* **450**, 936–941.
- Bolhassani, A., Gholami, E., Zahedifard, F., Moradin, N., Parsi, P., Doustdari, F., Seyed, N., Papadopoulou, B. and Rafati, S. (2011). *Leishmania major*: protective capacity of DNA vaccine using amastin fused to HSV-1 VP22 and EGFP in BALB/c mice model. *Experimental Parasitology* **128**, 9–17.
- Brand, K., Aichinger, S., Forster, S., Kupper, S., Neumann, B., Nurnberg, W. and Ohrlsch, G. (1988). Cell-cycle-related metabolic and enzymatic events in proliferating rat thymocytes. *European Journal of Biochemistry* **172**, 695–702.
- Britton, H.G., Carreras, J. and Grisolia, S. (1971). Mechanism of action of 2,3-diphosphoglycerate-independent phosphoglycerate mutase. *Biochemistry* **10**, 4522–4533.
- Carreras, J., Bartrons, R. and Grisolia, S. (1980). Vanadate inhibits 2,3-bisphosphoglycerate dependent phosphoglycerate mutases but does not affect the 2,3-bisphosphoglycerate independent phosphoglycerate mutases. *Biochemical and Biophysical Research Communications* **96**, 1267–1273.
- Chakravarty, J., Kumar, S., Trivedi, S., Rai, V.K., Singh, A., Ashman, J.A., Laughlin, E.M., Coler, R.N., Kahn, S.J., Beckmann, A.M., Cowgill, K.D., Reed, S.G., Sundar, S. and Piazza, F.M. (2001). A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. *Vaccine* **29**, 3531–3537.
- Chander, M., Setlow, P., Lamani, E. and Jedrzejas, M.J. (1999). Structural studies on a 2,3-diphosphoglycerate independent phosphoglycerate mutase from *Bacillus stearothermophilus*. *Journal of Structural Biology* **126**, 156–165.
- Chenna, R., Sugawara, H., Koike, T., Lopez, R., Gibson, T.J., Higgins, D.G. and Thompson, J.D. (2003). Multiple sequence alignment with the Clustal series of programs. *Nucleic Acids Research* **31**, 3497–3500.
- Chevalier, N., Rigden, D.J., Van Roy, J., Opperdoes, F.R. and Michels, P.A. (2000). *Trypanosoma brucei* contains a 2,3-bisphosphoglycerate independent phosphoglycerate mutase. *European Journal of Biochemistry* **267**, 1464–1472.
- Coler, R.N. and Reed, S.G. (2005). Second-generation vaccines against leishmaniasis. *Trends in Parasitology* **21**, 244–249.
- Coler, R.N., Skeiky, Y.A., Bernards, K., Greeson, K., Carter, D., Cornellison, C.D., Modabber, F., Campos-Neto, A. and Reed, S.G. (2002). Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, *Leishmania major* stress-inducible protein 1, and *Leishmania* elongation initiation factor protects against leishmaniasis. *Infection and Immunity* **70**, 4215–4225.
- Croft, S.L., Sundar, S. and Fairlamb, A.H. (2006). Drug resistance in leishmaniasis. *Clinical Microbiology Reviews* **19**, 111–126.
- Ding, A.H., Nathan, C.F. and Stuehr, D.J. (1988). Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. *Journal of Immunology* **141**, 2407–2412.
- Djikeng, A., Raverdy, S., Foster, J., Bartholomeu, D., Zhang, Y., El-Sayed, N.M. and Carlow, C. (2007). Cofactor-independent phosphoglycerate mutase is an essential gene in procyclic form *Trypanosoma brucei*. *Parasitology Research* **100**, 887–892.
- Dube, A., Singh, N. and Sundar, S. (2005). Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in vitro and in vivo experimental models. *Parasitology Research* **96**, 216–223.
- Erfe, M.C., David, C.V., Huang, C., Lu, V., Maretta-Mira, A.C., Haskell, J., Bruhn, K.W., Yeaman, M.R. and Craft, N. (2012). Efficacy of synthetic peptides RP-1 and AA-RP-1 against *Leishmania* species in vitro and in vivo. *Antimicrobial Agents and Chemotherapy* **56**, 658–665.
- Foster, J.M., Davis, P.J., Raverdy, S., Sibley, M.H., Raleigh, E.A., Kumar, S. and Carlow, C.K. (2010). Evolution of bacterial phosphoglycerate mutases: non-homologous isofunctional enzymes undergoing gene losses, gains and lateral transfers. *PLoS ONE* **5**, e13576.
- Fothergill-Gilmore, L.A. and Watson, H.C. (1989). The phosphoglycerate mutases. *Advances in Enzymology and Related Areas of Molecular Biology* **62**, 227–313.
- Garg, R., Gupta, S.K., Tripathi, P., Naik, S., Sundar, S. and Dube, A. (2005). Immunostimulatory cellular responses of cured *Leishmania*-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of *Leishmania donovani*. *Clinical and Experimental Immunology* **140**, 149–156.
- Garg, R., Gupta, S.K., Tripathi, P., Hajela, K., Sundar, S., Naik, S. and Dube, A. (2006). *Leishmania donovani*: identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis. *Vaccine* **24**, 2900–2909.
- Giege, P., Heazlewood, J.L., Roessner-Tunali, U., Millar, A.H., Fernie, A.R., Leaver, C.J. and Sweetlove, L.J. (2003). Enzymes of glycolysis are functionally associated with the mitochondrion in Arabidopsis cells. *Plant Cell* **15**, 2140–2151.
- Gizak, A., Grenda, M., Mamczur, P., Wisniewski, J., Sucharski, F., Silberring, J., McCubrey, J.A., Wisniewski, J.R. and Rakus, D. (2015). Insulin/IGF1-PI3K-dependent nucleolar localization of a glycolytic enzyme – phosphoglycerate mutase 2, is necessary for proper structure of nucleolus and RNA synthesis. *Oncotarget* **6**, 17237–17250.
- Guerra, D.G., Vertommen, D., Fothergill-Gilmore, L.A., Opperdoes, F.R. and Michels, P.A. (2004). Characterization of the cofactor-independent phosphoglycerate mutase from *Leishmania mexicana mexicana*. Histidines that coordinate the two metal ions in the active site show different susceptibilities to irreversible chemical modification. *European Journal of Biochemistry* **271**, 1798–1810.
- Gupta, R., Kushawaha, P.K., Tripathi, C.D., Sundar, S. and Dube, A. (2012). A novel recombinant *Leishmania donovani* p45, a partial coding region of methionine aminopeptidase, generates protective immunity by inducing a Th1 stimulatory response against experimental visceral leishmaniasis. *International Journal for Parasitology* **42**, 429–435.
- Gupta, S.K., Sisodia, B.S., Sinha, S., Hajela, K., Naik, S., Shasany, A.K. and Dube, A. (2007). Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of *Leishmania donovani* promastigotes. *Proteomics* **7**, 816–823.
- Handman, E. (2001). Leishmaniasis: current status of vaccine development. *Clinical Microbiology Reviews* **14**, 229–243.
- Holaday, B.J., Sadick, M.D., Wang, Z.E., Reiner, S.L., Heinzel, F.P., Parslow, T.G. and Locksley, R.M. (1991). Reconstitution of *Leishmania* immunity in severe combined immunodeficient mice using Th1- and Th2-like cell lines. *Journal of Immunology* **147**, 1653–1658.
- Jedrzejas, M.J., Chander, M., Setlow, P. and Krishnasamy, G. (2000). Mechanism of catalysis of the cofactor-independent phosphoglycerate mutase from *Bacillus stearothermophilus*. Crystal structure of the complex with 2-phosphoglycerate. *Journal of Biological Chemistry* **275**, 23146–23153.
- Karp, C.L., el-Safi, S.H., Wynn, T.A., Satti, M.M., Kordofani, A.M., Hashim, F.A., Hag-Ali, M., Neva, F.A., Nutman, T.B. and Sacks, D.L. (1993). In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. *The Journal of Clinical Investigation* **91**, 1644–1648.
- Kemp, K., Kemp, M., Kharazmi, A., Ismail, A., Kurtzhals, J.A., Hviid, L. and Theander, T.G. (1999). *Leishmania*-specific T cells expressing interferon-gamma (IFN-gamma) and IL-10 upon activation are expanded in individuals cured of visceral leishmaniasis. *Clinical and Experimental Immunology* **116**, 500–504.
- Kemp, M., Hey, A.S., Bendtzen, K., Kharazmi, A. and Theander, T.G. (1994). Th1-like human T-cell clones recognizing *Leishmania* gp63 inhibit *Leishmania major* in human macrophages. *Scandinavian Journal of Immunology* **40**, 629–635.
- Khalil, E.A., El Hassan, A.M., Zijlstra, E.E., Mukhtar, M.M., Ghalib, H.W., Musa, B., Ibrahim, M.E., Kamil, A.A., Elsheikh, M., Babiker, A. and Modabber, F. (2000). Autoclaved *Leishmania major* vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. *Lancet* **356**, 1565–1569.
- Khalil, E.A., Musa, A.M., Modabber, F. and El-Hassan, A.M. (2006). Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved *Leishmania major* + BCG) in children: an extended phase II study. *Annals of Tropical Paediatrics* **26**, 357–361.
- Kumar, R. and Engwerda, C. (2014). Vaccines to prevent leishmaniasis. *Clinical & Translational Immunology* **3**, e13.
- Kumar, R. and Nylen, S. (2012). Immunobiology of visceral leishmaniasis. *Frontiers in Immunology* **3**, 251.
- Kumari, S., Samant, M., Khare, P., Sundar, S., Sinha, S. and Dube, A. (2008a). Induction of Th1-type cellular responses in cured/exposed *Leishmania*-infected patients and hamsters against polyproteins

- of soluble *Leishmania donovani* promastigotes ranging from 89.9 to 97.1 kDa. *Vaccine* **26**, 4813–4818.
- Kumari, S., Samant, M., Misra, P., Khare, P., Sisodia, B., Shasany, A. K. and Dube, A.** (2008b). Th1-stimulatory polyproteins of soluble *Leishmania donovani* promastigotes ranging from 89.9 to 97.1 kDa offers long-lasting protection against experimental visceral leishmaniasis. *Vaccine* **26**, 5700–5711.
- Kumari, S., Misra, P., Tandon, R., Samant, M., Sundar, S. and Dube, A.** (2012). *Leishmania donovani*: immunostimulatory cellular responses of membrane and soluble protein fractions of splenic amastigotes in cured patient and hamsters. *PLoS ONE* **7**, e30746.
- Kushawaha, P. K., Gupta, R., Sundar, S., Sahasrabudhe, A. A. and Dube, A.** (2011). Elongation factor-2, a Th1 stimulatory protein of *Leishmania donovani*, generates strong IFN-gamma and IL-12 response in cured *Leishmania*-infected patients/hamsters and protects hamsters against *Leishmania* challenge. *Journal of Immunology* **187**, 6417–6427.
- Kushawaha, P. K., Gupta, R., Tripathi, C. D., Sundar, S. and Dube, A.** (2012). Evaluation of *Leishmania donovani* protein disulfide isomerase as a potential immunogenic protein/vaccine candidate against visceral leishmaniasis. *PLoS ONE* **7**, e35670.
- Laskowski, R. A., MacArthur, M. W., Moss, D. S. and Thornton, J. M.** (1993). PROCHECK: a program to check the stereochemical quality of protein structures. *Journal of Applied Crystallography* **26**, 283–291.
- Liew, F. Y., Li, Y., Moss, D., Parkinson, C., Rogers, M. V. and Moncada, S.** (1991). Resistance to *Leishmania major* infection correlates with the induction of nitric oxide synthase in murine macrophages. *European Journal of Immunology* **21**, 3009–3014.
- MacMicking, J., Xie, Q. W. and Nathan, C.** (1997). Nitric oxide and macrophage function. *Annual Review of Immunology* **15**, 323–350.
- Melby, P. C., Tryon, V. V., Chandrasekar, B. and Freeman, G. L.** (1998a). Cloning of Syrian hamster (*Mesocricetus auratus*) cytokine cDNAs and analysis of cytokine mRNA expression in experimental visceral leishmaniasis. *Infection and Immunity* **66**, 2135–2142.
- Melby, P. C., Yang, Y. Z., Cheng, J. and Zhao, W.** (1998b). Regional differences in the cellular immune response to experimental cutaneous or visceral infection with *Leishmania donovani*. *Infection and Immunity* **66**, 18–27.
- Melby, P. C., Chandrasekar, B., Zhao, W. and Coe, J. E.** (2001). The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. *Journal of Immunology* **166**, 1912–1920.
- Minocha, N., Kumar, D., Rajanala, K. and Saha, S.** (2011). Kinetoplast morphology and segregation pattern as a marker for cell cycle progression in *Leishmania donovani*. *Journal of Eukaryotic Microbiology* **58**, 249–253.
- Misra, A., Dube, A., Srivastava, B., Sharma, P., Srivastava, J. K., Katiyar, J. C. and Naik, S.** (2001). Successful vaccination against *Leishmania donovani* infection in Indian langur using alum-precipitated autoclaved *Leishmania major* with BCG. *Vaccine* **19**, 3485–3492.
- Motshwene, P., Brandt, W. and Lindsey, G.** (2003). Significant quantities of the glycolytic enzyme phosphoglycerate mutase are present in the cell wall of yeast *Saccharomyces cerevisiae*. *Biochemical Journal* **369**, 357–362.
- Murray, H. W., Hariprashad, J. and Coffman, R. L.** (1997). Behavior of visceral *Leishmania donovani* in an experimentally induced T helper cell 2 (Th2)-associated response model. *Journal of Experimental Medicine* **185**, 867–874.
- Nowicki, M. W., Kuaprasert, B., McNae, I. W., Morgan, H. P., Harding, M. M., Michels, P. A., Fothergill-Gilmore, L. A. and Walkinshaw, M. D.** (2009). Crystal structures of *Leishmania mexicana* phosphoglycerate mutase suggest a one-metal mechanism and a new enzyme subclass. *Journal of Molecular Biology* **394**, 535–543.
- Nozaki, Y., Hasegawa, Y., Ichiyama, S., Nakashima, I. and Shimokata, K.** (1997). Mechanism of nitric oxide-dependent killing of *Mycobacterium bovis* BCG in human alveolar macrophages. *Infection and Immunity* **65**, 3644–3647.
- Peruhype-Magalhaes, V., Martins-Filho, O. A., Prata, A., Silva Lde, A., Rabello, A., Teixeira-Carvalho, A., Figueiredo, R. M., Guimaraes-Carvalho, S. F., Ferrari, T. C. and Correa-Oliveira, R.** (2005). Immune response in human visceral leishmaniasis: analysis of the correlation between innate immunity cytokine profile and disease outcome. *Scandinavian Journal of Immunology* **62**, 487–495.
- Petersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C. and Ferrin, T. E.** (2004). UCSF Chimera – a visualization system for exploratory research and analysis. *Journal of Computational Chemistry* **25**, 1605–1612.
- Sali, A. and Blundell, T. L.** (1993). Comparative protein modelling by satisfaction of spatial restraints. *Journal of Molecular Biology* **234**, 779–815.
- Samant, M., Gupta, R., Kumari, S., Misra, P., Khare, P., Kushawaha, P. K., Sahasrabudhe, A. A. and Dube, A.** (2009). Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of *Leishmania donovani* generates Th1-type immunoprotective response against experimental visceral leishmaniasis. *Journal of Immunology* **183**, 470–479.
- Scott, P., Pearce, E., Heath, S. and Sher, A.** (1987). Identification of T-cell-reactive antigens that protect BALB/c mice against *Leishmania major*. *Annales de l'Institut Pasteur/Immunologie* **138**, 771–774.
- Singh, N., Kumar, R., Gupta, S., Dube, A. and Lakshmi, V.** (2008). Antileishmanial activity in vitro and in vivo of constituents of sea cucumber *Actinopyga lecanora*. *Parasitology Research* **103**, 351–354.
- Stober, C. B., Jeronimo, S. M., Pontes, N. N., Miller, E. N. and Blackwell, J. M.** (2012). Cytokine responses to novel antigens in a peri-urban population in Brazil exposed to *Leishmania infantum chagasi*. *American Journal of Tropical Medicine and Hygiene* **87**, 663–670.
- Sundar, S. and Chatterjee, M.** (2006). Visceral leishmaniasis – current therapeutic modalities. *Indian Journal of Medical Research* **123**, 345–352.
- Sundar, S., Pai, K., Kumar, R., Pathak-Tripathi, K., Gam, A. A., Ray, M. and Kenney, R. T.** (2001). Resistance to treatment in Kala-azar: speciation of isolates from northeast India. *American Journal of Tropical Medicine and Hygiene* **65**, 193–196.
- Von Stebut, E.** (2015). Leishmaniasis. *Journal der Deutschen Dermatologischen Gesellschaft* **13**, 191–200; quiz 201.
- Wang, J. L., Walling, L. L., Jauh, G. Y., Gu, Y. Q. and Lord, E. M.** (1996). Lily cofactor-independent phosphoglycerate mutase: purification, partial sequencing, and immunolocalization. *Planta* **200**, 343–352.